CA2880648A1 - Methods for treatment of atherosclerosis - Google Patents
Methods for treatment of atherosclerosis Download PDFInfo
- Publication number
- CA2880648A1 CA2880648A1 CA2880648A CA2880648A CA2880648A1 CA 2880648 A1 CA2880648 A1 CA 2880648A1 CA 2880648 A CA2880648 A CA 2880648A CA 2880648 A CA2880648 A CA 2880648A CA 2880648 A1 CA2880648 A1 CA 2880648A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- simvastatin
- arg
- release
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678992P | 2012-08-02 | 2012-08-02 | |
| US61/678,992 | 2012-08-02 | ||
| US201261695807P | 2012-08-31 | 2012-08-31 | |
| US201261695850P | 2012-08-31 | 2012-08-31 | |
| US61/695,850 | 2012-08-31 | ||
| US61/695,807 | 2012-08-31 | ||
| PCT/US2013/053008 WO2014022552A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2880648A1 true CA2880648A1 (en) | 2014-02-06 |
Family
ID=50028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2880648A Abandoned CA2880648A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
| CA2880643A Abandoned CA2880643A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2880643A Abandoned CA2880643A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10188693B2 (enExample) |
| EP (6) | EP2879688A4 (enExample) |
| JP (5) | JP2015524439A (enExample) |
| CN (3) | CN110090304A (enExample) |
| AU (4) | AU2013296493B2 (enExample) |
| CA (2) | CA2880648A1 (enExample) |
| HK (2) | HK1210962A1 (enExample) |
| WO (2) | WO2014022552A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858550A1 (en) * | 2011-12-09 | 2013-06-13 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10188693B2 (en) * | 2012-08-02 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods for treatment of atherosclerosis |
| EP4397314B1 (en) * | 2012-10-22 | 2025-12-03 | Stealth BioTherapeutics Inc. | Treatment of left ventricular remodeling |
| WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
| WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
| RU2623876C2 (ru) * | 2014-11-10 | 2017-06-29 | Александр Владимирович Диковский | Фармацевтическая композиция для лечения гиперлипидемии |
| WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
| US20180318381A1 (en) * | 2015-10-23 | 2018-11-08 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Methods of Treatment of Rhabdomyolysis |
| US11355245B2 (en) * | 2016-05-03 | 2022-06-07 | International Business Machines Corporation | Identifying and ranking risk factors using trained predictive models |
| ES2871783T3 (es) * | 2016-09-20 | 2021-11-02 | Univ Aarhus | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas |
| CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| GB202005439D0 (en) | 2020-04-14 | 2020-05-27 | Aurigen Medical Ltd | A device for occlusion of a left a trial appendage of a heart |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| AU2002336959B2 (en) | 2001-08-10 | 2006-07-13 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| EP3167935B1 (en) * | 2003-05-01 | 2018-07-18 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP3725324A1 (en) * | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| CA2640615A1 (en) * | 2006-01-30 | 2007-08-09 | Israel Ben David Bryson | Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients |
| WO2008026702A1 (fr) | 2006-08-30 | 2008-03-06 | Kyushu University, National University Corporation | Composition pharmaceutique contenant une nanoparticule de statine encapsulée |
| WO2009092073A2 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| EP2712620A1 (en) * | 2008-02-07 | 2014-04-02 | Cornell University | Methods for Preventing or Treating Insulin Resistance |
| CA2770688C (en) | 2009-08-12 | 2018-06-05 | Cornell University | Methods for preventing or treating metabolic syndrome |
| SI3708178T1 (sl) * | 2009-08-24 | 2024-01-31 | Stealth Biotherapeutics Inc. | Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule |
| EP3332795A1 (en) * | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP2808029A3 (en) | 2010-03-15 | 2015-04-01 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
| US10188693B2 (en) * | 2012-08-02 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods for treatment of atherosclerosis |
-
2013
- 2013-07-31 US US14/418,827 patent/US10188693B2/en active Active
- 2013-07-31 EP EP13824883.6A patent/EP2879688A4/en not_active Withdrawn
- 2013-07-31 EP EP16174236.6A patent/EP3132800A1/en not_active Withdrawn
- 2013-07-31 HK HK15111866.1A patent/HK1210962A1/xx unknown
- 2013-07-31 WO PCT/US2013/053008 patent/WO2014022552A1/en not_active Ceased
- 2013-07-31 CN CN201910002871.XA patent/CN110090304A/zh active Pending
- 2013-07-31 HK HK15111769.9A patent/HK1210953A1/xx unknown
- 2013-07-31 EP EP19209275.7A patent/EP3662921A1/en not_active Withdrawn
- 2013-07-31 CN CN201380049762.4A patent/CN104768564A/zh active Pending
- 2013-07-31 EP EP18198495.6A patent/EP3485897A1/en not_active Withdrawn
- 2013-07-31 EP EP13825389.3A patent/EP2879689A4/en not_active Withdrawn
- 2013-07-31 CN CN201380049785.5A patent/CN104661670A/zh active Pending
- 2013-07-31 AU AU2013296493A patent/AU2013296493B2/en active Active
- 2013-07-31 CA CA2880648A patent/CA2880648A1/en not_active Abandoned
- 2013-07-31 WO PCT/US2013/053007 patent/WO2014022551A1/en not_active Ceased
- 2013-07-31 JP JP2015525555A patent/JP2015524439A/ja active Pending
- 2013-07-31 US US14/418,809 patent/US10201585B2/en active Active
- 2013-07-31 JP JP2015525554A patent/JP2015529655A/ja active Pending
- 2013-07-31 AU AU2013296494A patent/AU2013296494B2/en active Active
- 2013-07-31 EP EP17186931.6A patent/EP3300740A1/en not_active Withdrawn
- 2013-07-31 CA CA2880643A patent/CA2880643A1/en not_active Abandoned
-
2017
- 2017-10-04 JP JP2017194137A patent/JP2018016637A/ja active Pending
- 2017-10-06 JP JP2017195835A patent/JP2018012726A/ja active Pending
- 2017-12-20 US US15/848,198 patent/US20180344797A1/en not_active Abandoned
- 2017-12-20 US US15/848,712 patent/US20180339012A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202068A patent/AU2018202068A1/en not_active Abandoned
- 2018-03-27 AU AU2018202197A patent/AU2018202197A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/271,185 patent/US20200000870A1/en not_active Abandoned
- 2019-03-08 JP JP2019042213A patent/JP2019108389A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10188693B2 (en) | Methods for treatment of atherosclerosis | |
| JP7072692B2 (ja) | バース症候群の予防または治療のための方法及び組成物 | |
| JP6641356B2 (ja) | 疾患の予防及び治療のための方法及び組成物 | |
| HK1249428A1 (zh) | 预防或治疗缺血/再灌注损伤之後无复流的方法 | |
| US9884085B2 (en) | Methods for the regulation of matrix metalloproteinase expression | |
| HK40007041A (en) | D-arg-2'6'-dmt-lys-phe-nh2 for decreasing statin side effects | |
| US11931397B2 (en) | Methods and compositions for the treatment of Sengers syndrome | |
| CA2912386C (en) | Methods for the prevention or treatment of left ventricular remodeling | |
| HK40061712B (en) | D-arg-2'6'-dmt-lys-phe-nh2 for use in treating or preventing sengers syndrome | |
| HK40061712A (en) | D-arg-2'6'-dmt-lys-phe-nh2 for use in treating or preventing sengers syndrome | |
| HK40019493A (en) | Methods and compositions for the prevention or treatment of barth syndrome | |
| CA2912386A1 (en) | Methods for the prevention or treatment of left ventricular remodeling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190731 |